Por: The Boston Globe Business September 29, 2022
Promising results from a trial of an experimental drug for Alzheimer’s made by Biogen and its Japanese partner Eisai are reviving hopes that an effective treatment for the devastating condition that’s long baffled the medical world may finally be at hand.In what some researchers are calling the biggest advance ever in treating Alzheimer’s, the companies reported late Tuesday that the drug, called lecanemab, appeared to slow the progress of... + full article
ABC News USA Business September 29, 2022
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared Wednesday after ’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab, reduced... + más
COVID-19 in seniors linked to increased Alzheimer’s risk, study finds | Portland Press Herald
How To Spot The Early Signs Of Alzheimer's | Newsweek
The Boston Globe USA Business September 28, 2022
Biogen and its partner Eisai said Tuesday night that their experimental Alzheimer’s disease therapy successfully slowed the memory-robbing condition in a large clinical trial. The results set the stage for potential approval of the drug next year.Although far from a cure, the... + más
Alzheimer's drug shows promise in early results of study | WPLG Local 10
Alzheimer's drug shows promise in early results of study | ABC News
Fox Business USA Business September 28, 2022
Dr. Stephen O'Brien, chief medical officer of Mediflix, shares how his streaming platform is trailblazing access to medical information for everyone. Shares of Biogen surged Wednesday's following news that its drug lecanemab showed promising signs of potentially... + más
Biogen shares rally as Alzheimer's drug results show promise | CBS News
CBS News USA Health September 28, 2022
Shares of Biogen and Japanese pharmaceutical company Eisai jumped Wednesday after the drug makers said their potential treatment for Alzheimer's showed promise in slowing the fatal disease that afflicts more than 6 million Americans. The companies late Tuesday results... + más
Biogen shares soar on Alzheimer's drug developments | Fox Business
WPLG Local 10 USA Health September 28, 2022
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab,... + más
Associated Press USA Health September 28, 2022
Portland Press Herald USA Health September 24, 2022
A study using the electronic health records of more than 6 million Americans over age 65 found that those who had COVID-19 ran a greater risk of receiving a new diagnosis of Alzheimer’s disease within a year. The study, led by researchers at Case Western Reserve University... + más
There's a growing dementia crisis in the veteran community: Alzheimer's Q&A | The Advocate
About iurex | Privacy Policy | Disclaimer |